Shots:

• Nimbus will receive $4B up front, ~$2B in commercial-related milestones upon achievement of annual net sales of $4B & $5B. The transaction is expected to be close before the end of 2022
• The acquisition expands Takeda’s late-stage pipeline & therapeutic expertise in immune-mediated diseases. Nimbus will retain ownership of its other R&D subsidiaries
• Takeda will lead the future development & commercialization of NDI-034858, an allosteric Tyk2 inhibitor that was developed by Nimbus & is being evaluated in P-IIb trials for multiple autoimmune diseases & other Tyk2 inhibitors. The P-IIb results are expected to present in early 2023 for PsO & the P-III trial of NDI-034858 is expected to be initiated in 2023 for psoriasis

Ref: Takeda | Image: Takeda